8 results about "Bivalirudin" patented technology

The invention discloses a copper ion mediated bivalirudin self-assembled nano-drug and a preparation method and application thereof, and belongs to the field of biological medicines.The preparation method comprises the following steps that bivalirudin and targeting peptide cRGD are dissolved in an organic solvent, copper salt is dissolved in deionized water, the organic solution and an aqueous solution are mixed, the pH is adjusted to be faintly acid or neutral, and the copper ion mediated bivalirudin self-assembled nano-drug is obtained; and fully stirring and reacting to obtain a suspension, centrifuging to remove supernate, and freeze-drying to obtain the freeze-dried powder. On the basis of a metal coordination polypeptide self-assembly strategy, metal ions are introduced on the basis of traditional polypeptide self-assembly, special reaction performance is introduced through coordination of polypeptide functional groups and the metal ions to participate in regulation and control of the polypeptide self-assembly process, and thrombus targeting peptide is introduced on the basis to achieve precise drug delivery at the thrombus part.

Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.

The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of ginseng polypeptide. The ginseng active polypeptide is prepared by carrying out enzymolysis reaction on ginseng protein. The ginseng active polypeptide can effectively inhibit the activity of thrombin, so that the ginseng active polypeptide can be used as a thrombosis inhibitor to treat cardiovascular and cerebrovascular diseases such as myocardial infarction and ischemic stroke. The plant extract disclosed by the invention not only has an antithrombotic effect, but also has the advantages of no toxicity, no side effect, simplicity in preparation, easiness in absorption and the like, and the adverse effects of side effects of traditional chemical medicines such as bivalirudin and other thrombus inhibitors on human bodies are avoided.

The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.

The invention discloses a bivalirudin-protein coating as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The bivalirudin-protein coating comprises a bivalirudin-protein layer arranged on the surface of a base material, the bivalirudin-protein layer is formed by carrying out structural rearrangement on a bivalirudin-protein co-assembly coating with a micro-nano pore structure in the presence of an anion solution. The bivalirudin-protein coating is good in stability and high in density, and can realize long-acting and controllable slow release compared with the bivalirudin, so that a modified base material is endowed with an excellent long-acting anticoagulant effect, and the bivalirudin-protein coating can be used for preparing blood contact devices and the like. The preparation method comprises the following steps: mixing a base material with a mixed solution containing an oxidizing agent, bivalirudin and protein, so that bivalirudin and protein are subjected to a co-assembly reaction, and a co-assembly coating with a micro-nano pore structure is obtained; the co-assembled coating is mixed with an anion solution, so that the co-assembled coating is subjected to structural rearrangement to realize self-packaging.

The present application belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to an antithrombotic polypeptide PM4 and application thereof. The present application is based on an original polypeptide obtained from a transcriptome of a leech salivary gland and an amino acid fragment cut from the original polypeptide, increases {d-Phe}-PRP at an N terminal of the cut amino acid fragment through a synthesis strategy of a hirudin analogue drug bivalirudin, and finally connects the {d-Phe}-PRP and the cut amino acid fragment through a connecting polypeptide to obtain the antithrombotic polypeptide PM4. The antithrombotic polypeptide PM4 can inhibit the activity of thrombin, has a small risk of bleeding, a shorter half-life in the body, higher safety, and significant resistance to thrombosis including arterial thrombosis. Meanwhile, the sequence of the antithrombotic polypeptide PM4 is shorter than the original sequence and is easier to synthesize.

This invention belongs to the field of polypeptide synthesis and biomedical technology, specifically relating to a derived polypeptide PM6 and its application in antithrombosis. The invention obtains the original polypeptide SEQ ID NO:1 from the transcriptome of the salivary glands of *Hirudo medicinalis*, and then obtains a truncated polypeptide as shown in SEQ ID NO:3. Based on this, using a synthetic strategy similar to that of the hirudin analog *Bivalirudin*, {d-Phe}-PRP is added to the N-terminus of the truncated amino acid sequence. The {d-Phe}-PRP is then linked to the truncated polypeptide using a linker polypeptide to obtain the derived polypeptide PM6. The derived polypeptide PM6 of this invention exhibits good antithrombotic activity, and its bleeding risk is comparable to that of the positive control drug bilivadin.

This invention discloses a method for preparing a bioprosthetic valve with synergistic anticoagulant and antioxidant functions, comprising: Step 1, immersing a decellularized bioprosthetic valve matrix in a buffer solution containing carbodiimide, N-hydroxysuccinimide, and tyramine; Step 2, immersing the tyramine-grafted bioprosthetic valve matrix obtained in Step 1 in a solution containing the direct thrombin inhibitor bivalirudin; subsequently adding tyrosine oxidase for catalytic reaction; Step 3, immersing the bivalirudin-immobilized bioprosthetic valve obtained in Step 2 in a cerium nitrate solution for reaction; adjusting the pH to an alkaline environment to form cerium oxide nanoparticles in situ. This invention also provides a bioprosthetic valve with synergistic anticoagulant and antioxidant functions. This invention simultaneously enhances the mechanical properties of the matrix and constructs a bioactive interface in a single reaction step. The method is simple and efficient. It also exhibits synergistic anticoagulant effects, multifunctional integration, and long-term stability.